Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Ocular Therapeutix, Inc is a biotechnology business based in the US. Ocular Therapeutix shares (OCUL) are listed on the NASDAQ and all prices are listed in US Dollars. Ocular Therapeutix employs 181 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$14.56|
|52-week range||$7.14 - $24.30|
|50-day moving average||$13.70|
|200-day moving average||$16.77|
|Wall St. target price||$25.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.79|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-07-18)||N/A|
|1 month (2021-06-29)||5.81%|
|3 months (2021-04-29)||-24.01%|
|6 months (2021-01-25)||N/A|
|1 year (2020-07-25)||N/A|
|2 years (2019-07-25)||N/A|
|3 years (2018-07-25)||N/A|
|5 years (2016-07-25)||N/A|
|Revenue TTM||$22.1 million|
|Gross profit TTM||$-13,374,000|
|Return on assets TTM||-26.3%|
|Return on equity TTM||-360.15%|
|Market capitalisation||$924.7 million|
TTM: trailing 12 months
There are currently 5.8 million Ocular Therapeutix shares held short by investors – that's known as Ocular Therapeutix's "short interest". This figure is 10% down from 6.5 million last month.
There are a few different ways that this level of interest in shorting Ocular Therapeutix shares can be evaluated.
Ocular Therapeutix's "short interest ratio" (SIR) is the quantity of Ocular Therapeutix shares currently shorted divided by the average quantity of Ocular Therapeutix shares traded daily (recently around 813597.33893557). Ocular Therapeutix's SIR currently stands at 7.14. In other words for every 100,000 Ocular Therapeutix shares traded daily on the market, roughly 7140 shares are currently held short.
However Ocular Therapeutix's short interest can also be evaluated against the total number of Ocular Therapeutix shares, or, against the total number of tradable Ocular Therapeutix shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ocular Therapeutix's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Ocular Therapeutix shares in existence, roughly 80 shares are currently held short) or 0.0869% of the tradable shares (for every 100,000 tradable Ocular Therapeutix shares, roughly 87 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Ocular Therapeutix.
Find out more about how you can short Ocular Therapeutix stock.
We're not expecting Ocular Therapeutix to pay a dividend over the next 12 months.
Over the last 12 months, Ocular Therapeutix's shares have ranged in value from as little as $7.14 up to $24.3. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ocular Therapeutix's is 2.0598. This would suggest that Ocular Therapeutix's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Ocular Therapeutix, Inc. , a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant administered by the fine-gauge needle that is in phase 1 clinical trial for the treatment of wet age-related macular degeneration; OTX-TIC, a travoprost intracameral implant, which is in phase 1 clinical trial for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that is in phase 2 clinical trial for the chronic treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trial for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company is involved in the development of OTX-AFS, an aflibercept suprachoroidal injection for the treatment of retinal diseases. It has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of Dry Age-related Macular Degeneration.
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.